All data is delayed
Loading...
See More

SA, Swiss firm in $211m drug venture

Feb 10 2012 14:10
Reuters
Cape Town - South Africa will set up a $211m joint venture with Swiss firm Lonza Group to manufacture the main chemicals used in HIV drugs, a senior official said on Friday, as part of a government plan to lower prices of critical drugs.

South Africa, which has the world’s heaviest HIV caseload and its biggest treatment programme, has long complained that it pays too much to secure life-prolonging anti-retroviral drugs for state hospitals.

“This joint venture ... will establish the first pharmaceutical plant to manufacture active pharmaceutical ingredients for anti-retroviral medicines in South Africa,” said Science and Technology Minister Naledi Pandor.
 
Active Pharmaceutical Ingredients, or API, refers to the main component in medicines, accounting for as much as 75% of the finished drug dosage.

South Africa wants to produce ARVs in the country by 2016, a move that could squeeze local players such as Aspen, Cipla Medpro and Adcock Ingram,

SA consumes 25% of ARVs in the world and has at least 5.7 million people infected with the deadly virus.
 
Health authorities said in December 2010 10 companies that include Chicago-based Abbott Laboratories and India’s Aurobindo Pharma would share in a R4.3bn contract to supply ARVs.

The R1.6bn venture will build a plant in Pretoria that will create 2 200 jobs, with an additional 3 800 jobs to be created during the construction phase.
arvs  |  south africa

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

We're talking about:

SMALL BUSINESS

Myths that funding and red tape are the two biggest challenges faced by emerging companies and entrepreneurs, have been debunked by a report.
 

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

Sarb’s possible intervention in the markets to stem the rand’s fall is:

Previous results · Suggest a vote

Loading...